- Home
- MUR vs LNTH Comparison
MUR vs LNTH Comparison
Compare MUR & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUR | LNTH |
|---|---|---|
| Founded | 1950 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.7B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MUR | LNTH |
|---|---|---|
| Price | $38.85 | $105.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 6 |
| Target Price | $34.36 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 1.5M | 807.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.37 | ★ 1.80 |
| Revenue | ★ $2,718,823,000.00 | $343,374,000.00 |
| Revenue This Year | $9.45 | N/A |
| Revenue Next Year | $3.94 | $14.19 |
| P/E Ratio | $106.49 | ★ $57.63 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $21.86 | $47.27 |
| 52 Week High | $43.34 | $111.86 |
Technical Indicators
Market Signals| Indicator | MUR | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 64.37 | 51.22 |
| Support Level | $35.55 | $99.63 |
| Resistance Level | $40.83 | $111.86 |
| Average True Range (ATR) | 1.06 | 3.77 |
| MACD | 0.73 | -0.49 |
| Stochastic Oscillator | 85.54 | 55.43 |
Price Performance
Historical ComparisonAbout MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States. The company also generates revenue from sales of oil and natural gas production activities.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.